Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia

[1]  C. Gasse,et al.  C‐reactive protein levels and treatment resistance in schizophrenia—A Danish population‐based cohort study , 2017, Human psychopharmacology.

[2]  R. Murray,et al.  Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies , 2017, British Journal of Psychiatry.

[3]  C. Gasse,et al.  Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia , 2017, Schizophrenia bulletin.

[4]  R. Murray,et al.  Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis , 2017, The lancet. Psychiatry.

[5]  C. Gasse,et al.  Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. , 2017, The American journal of psychiatry.

[6]  R. Murray,et al.  Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study , 2017, Social Psychiatry and Psychiatric Epidemiology.

[7]  K. Murphy,et al.  Remission and recovery from first-episode psychosis in adults: A systematic review and meta-analysis of long-term outcome studies , 2017, European Psychiatry.

[8]  H. Möller,et al.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. , 2017, The American journal of psychiatry.

[9]  R. Murray,et al.  Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses , 2016, Psychological Medicine.

[10]  P. Mortensen,et al.  Inverse association between urbanicity and treatment resistance in schizophrenia , 2016, Schizophrenia Research.

[11]  C. Gasse,et al.  Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. , 2016, The lancet. Psychiatry.

[12]  P. Buckley,et al.  Treatment-Resistant Schizophrenia. , 2007, The Psychiatric clinics of North America.

[13]  Dollfus,et al.  Predictors of Treatment Resistance in Patients with Schizophrenia : a Population-based Cohort Study , 2016 .

[14]  R. Murray,et al.  Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. , 2014, Schizophrenia bulletin.

[15]  C. Altar,et al.  The social and economic burden of treatment-resistant schizophrenia: a systematic literature review , 2014, International clinical psychopharmacology.

[16]  S. Woods,et al.  Dose equivalents for second-generation antipsychotics: the minimum effective dose method. , 2014, Schizophrenia bulletin.

[17]  R. Murray,et al.  Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study , 2014, Psychological Medicine.

[18]  A. Wheeler,et al.  Pathway to Clozapine Use: A Comparison Between a Patient Cohort from New Zealand and a Cohort from the United Kingdom , 2014, Clinical Drug Investigation.

[19]  Jennifer I. Manuel,et al.  Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. , 2012, Psychiatric services.

[20]  Shitij Kapur,et al.  Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation , 2012, British Journal of Psychiatry.

[21]  Graham Thornicroft,et al.  The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data , 2009, BMC psychiatry.

[22]  M. Lambert,et al.  Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors , 2008 .

[23]  A. Mathai,et al.  Understanding and using sensitivity, specificity and predictive values , 2008, Indian journal of ophthalmology.

[24]  G. Dunn,et al.  Remission and relapse in psychosis: operational definitions based on case-note data , 2006, Psychological Medicine.

[25]  Nice.  Schizophrenia: core interventions in the treatment and management , 2005 .

[26]  E. Susser,et al.  Reliability of the Life Chart Schedule for assessment of the long-term course of schizophrenia , 2000, Schizophrenia Research.

[27]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.